BellaSeno Touts Positive Study Results for its Breast Scaffolds

Ten breast scaffold patients and five pectus patients have successfully passed a one-year follow-up in BellaSeno GmbH’s Australian clinical trials evaluating is breast implant.
 
In the first-ever breast implant trial using PCL scaffolds and fat transfer, the interim analysis confirms a favorable safety profile of the company´s resorbable soft tissue implants. No major complications such as capsular contracture, calcifications, oil cysts, infections, tissue necrosis, or wound healing issues were observed. Moreover, no scaffold removals or replacements were necessary, and no scaffold-related complications were observed in any patients six months post-surgery. 

“All patients have had consistently favorable outcomes in the follow-up ranging from six months to two years. We’re excited by the progress and at the end of this year will publish the detailed one-year interim analysis for the scientific community,” said Professor Owen Ung, primary investigator in the clinical trial.
 
Data review by the Independent Data Safety Monitoring Committee confirmed that all adverse events were within the expected range of complications for removal/replacement surgeries. In general, the clinical investigators observed a trend towards higher patient satisfaction with breasts and quality of life associated with BellaSeno´s scaffolds compared to baseline (i.e. silicone implants). There was high acceptability and patients did not report awareness of the scaffold in situ after six to 12 months. Identical findings were made in the one-year follow up in pectus excavatum patients.
 
Based on the positive data, BellaSeno plans to initiate a pivotal clinical trial to obtain regulatory approval of the breast scaffolds. 
 
“Following this favorable interim analysis, we are now well positioned to begin our pivotal clinical study to obtain full regulatory approval of our breast scaffolds in Europe and the U.S.,” BellaSeno CEO Mohit Chhaya stated. “We are excited that our resorbable scaffolds do not only meet the desired safety criteria but have also shown an improvement of patients´ quality of life.” 
 
So far, 41 patients have been successfully operated and received BellaSeno´s hard or soft tissue scaffolds (five bone scaffolds, 36 breast or pectus scaffolds). 
 
Established in 2015, BellaSeno GmbH is headquartered on the BioCity campus in Leipzig, Germany, and operates a subsidiary in Brisbane, Australia. The company is developing resorbable soft tissue and bone reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification. The company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB), the European Fund for Regional Development (EFRE), Germany´s Federal Ministry of Education and Research (BMBF), and the Australian government. BellaSeno has been co-funded from tax resources based on the budget adopted by the members of Saxony State Parliament.